SCHEMBL2669303

SCHEMBL2669303

NC(CC(F)(F)F)C(=O)Nc1ccc(Cl)cn1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ TSHR P16473 3/20 0.50
▸ PTK2 Q05397 1/20 0.50
▸ TDP1 Q9NUW8 3/20 0.49
▸ BRD4 O60885 1/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ GLA P06280 1/20 0.45
▸ THRB P10828 1/20 0.44
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669302 0.75 TRPA1 (0.48) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL208502 0.75 L3MBTL1 (0.68) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL2669275 0.74 L3MBTL1 (0.49) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL19699552 0.73 L3MBTL1 (0.68) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL29806129 0.72 L3MBTL1 (0.67) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL29806209 0.72 L3MBTL1 (0.67) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL5032454 0.71 L3MBTL1 (0.72) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL29078002 0.71 L3MBTL1 (0.65) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL27596585 0.71 L3MBTL1 (0.72) L3MBTL1TSHRPTK2TDP1BRD4
SCHEMBL29078001 0.71 L3MBTL1 (0.65) L3MBTL1MAPK1TSHRPTK2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034822-B2 Glucokinase activators TAKEDA SAN DIEGO, INC. (US) 2011-10-11 — — US disclosed
WO-2007104034-A2 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. (US) 2007-09-13 — — WO disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 — — US disclosed
US-20070213349-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213349-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 L3MBTL1 4723/4885MAPK1 818/4885TSHR 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback